Relief Therapeutics Updates on Potential Merger with Renexxion

Relief Therapeutics Holding SA, a biopharmaceutical company focused on treating specialty, unmet, and rare diseases, has provided an update regarding its potential reverse merger with Renexxion, Inc. The U.S.-based biotechnology company specializes in therapies for gastrointestinal disorders.

Following a non-binding letter of intent earlier this year, both companies have progressed significantly in planning this strategic partnership. They are currently focused on transaction structuring and integration planning to support future growth. A definitive merger agreement is expected by Q1 2025.

Despite positive discussions, there is no assurance that an agreement will be finalized or the transaction completed as planned. The potential merger remains subject to customary conditions.